Tumor progression was suppressed by bioengineered tRNA/miR-34a prodrug in a subcutaneous murine xenograft tumor model.

(A) Timeline of cell inoculation, drug administration and monitoring of tumor growth. For evaluation of early pharmacodynamics (PD) effects, three mice from the tRNA/miR-34a and three mice from the tRNA/MSA group were sacrificed 24 hours after last dose. (B) Monitoring of the mice weight during prodrug administration in each group. (C) Xenograft tumor growth in athymic nude mice treated with vehicle, tRNA/MSA or tRNA/miR-34a. Data (mean±SEM) were analyzed by repeated-measures two-way ANOVA followed by Bonferroni multiple-comparison test (*p p 3, were generated by the Kaplan-Meier method and survival differences between groups compared using log-rank (Mantel-Cox) analysis.